



HAL
open science

Mixed mucosal-parenteral immunizations with the broadly conserved pathogenic Escherichia coli antigen SslE induce a robust mucosal and systemic immunity without affecting the murine intestinal microbiota

Ilham Naili, Juliette Vinot, Barbara Baudner, Annick Bernalier Donadille, Mariagrazia Pizza, Mickaël Desvaux, Grégory Jubelin, Ugo d'Oro, Cecilia Buonsanti

► **To cite this version:**

Ilham Naili, Juliette Vinot, Barbara Baudner, Annick Bernalier Donadille, Mariagrazia Pizza, et al.. Mixed mucosal-parenteral immunizations with the broadly conserved pathogenic Escherichia coli antigen SslE induce a robust mucosal and systemic immunity without affecting the murine intestinal microbiota. *Vaccine*, 2019, 37 (2), pp.314-324. 10.1016/j.vaccine.2018.10.008 . hal-02909578

HAL Id: hal-02909578

<https://hal.inrae.fr/hal-02909578v1>

Submitted on 30 Jul 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Mixed mucosal-parenteral immunizations with the broadly conserved pathogenic *Escherichia coli* antigen SsIE induce a robust mucosal and systemic immunity without affecting the murine intestinal microbiota



Ilham Naili^{a,b,*}, Juliette Vinot^a, Barbara C. Baudner^a, Annick Bernalier-Donadille^b, Mariagrazia Pizza^a, Mickaël Desvaux^b, Grégory Jubelin^b, Ugo D'Oro^a, Cecilia Buonsanti^{a,*}

^a GSK, Siena, Italy

^b Université Clermont Auvergne, INRA, UMR454 MEDiS, 63000 Clermont-Ferrand, France

ARTICLE INFO

Article history:

Received 4 December 2017

Received in revised form 25 September 2018

Accepted 2 October 2018

Available online 30 November 2018

Keywords:

Immunization
Intranasal
Intramuscular
SsIE
Pathogenic *E. coli*
Gut microbiota

ABSTRACT

Emergence and dissemination of multidrug resistance among pathogenic *Escherichia coli* have posed a serious threat to public health across developing and developed countries. In combination with a flexible repertoire of virulence mechanisms, *E. coli* can cause a vast range of intestinal (InPEC) and extraintestinal (ExPEC) diseases but only a very limited number of antibiotics still remains effective against this pathogen. Hence, a broad spectrum *E. coli* vaccine could be a promising alternative to prevent the burden of such diseases, while offering the potential for covering against several InPEC and ExPEC at once. SsIE, the Secreted and Surface-associated Lipoprotein of *E. coli*, is a widely distributed protein among InPEC and ExPEC. SsIE functions *ex vivo* as a mucinase capable of degrading mucins and reaching the surface of mucus-producing epithelial cells. SsIE was identified by reverse vaccinology as a protective vaccine candidate against an ExPEC murine model of sepsis, and further shown to be cross-effective against other ExPEC and InPEC models of infection. In this study, we aimed to gain insight into the immune response to antigen SsIE and identify an immunization strategy suited to generate robust mucosal and systemic immune responses. We showed, by analyzing T cell and antibody responses, that mice immunized with SsIE via an intranasal prime followed by two intramuscular boosts developed an enhanced overall immune response compared to either intranasal-only or intramuscular-only protocols. Importantly, we also report that this regimen of immunization did not impact the richness of the murine gut microbiota, and mice had a comparable cecal microbial composition, whether immunized with SsIE or PBS. Collectively, our findings further support the use of SsIE in future vaccination strategies to effectively target both InPEC and ExPEC while not perturbing the resident gut microbiota.

© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Escherichia coli is a multifaceted Gram-negative bacterial organism. More than a laboratory workhorse, *E. coli* also colonizes and thrives within the healthy mammalian gut microbiota as a harmless facultative anaerobe. However, the remarkable ability of *E. coli* to allow for acquisition and loss of genetic material by horizontal gene transfer has driven the appearance of multiple

pathogenic variants of *E. coli* via successful combinations of virulence factors. Today, at least nine different pathogenic variants, or pathotypes, account for the high versatility of *E. coli*. These pathotypes cause a wide range of human diseases, which bare the potential to be lethal, and carry a significant economic and public health burden.

The six commonly studied pathotypes within intestinal pathogenic *E. coli* (InPEC) are responsible for diarrheal diseases of various severity along the gastrointestinal (GI) tract, and differ by their mechanism of colonization and virulence, as well as the clinical symptoms they provoke [1–3]. A recently published comprehensive study by the World Health Organization (WHO) on the global burden of foodborne diseases estimated that in 2010, InPEC were responsible for over 324 million cases of diarrheal diseases, with more than one third of it affecting children under 5 years of age

* Corresponding authors at: INRA (Institut National de la Recherche Agronomique), Auvergne-Rhône-Alpes, Centre de Recherche de Clermont-Ferrand, UMR454 MEDiS (Microbiologie, Environnement Digestif, Santé), Site de Theix, F-63122 Saint-Genès Champanelle, France (I. Naili). GSK, Via Fiorentina, 1, 53100, Siena, Italy (C. Buonsanti).

E-mail addresses: ilham.naili@gmail.com (I. Naili), cecilia.x.buonsanti@gsk.com (C. Buonsanti).

<https://doi.org/10.1016/j.vaccine.2018.10.008>

0264-410X/© 2018 The Authors. Published by Elsevier Ltd.

This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

[4]. Among these cases, enteropathogenic *E. coli* (EPEC) was the second leading cause of deaths from diarrheal diseases in the world. Extraintestinal pathogenic *E. coli* (ExPEC) can invade distant sites like the urinary tract, the bloodstream or the central nervous system [2]. Among ExPEC, uropathogenic *E. coli* (UPEC) is the main etiological agent of urinary tract infections (UTIs), accounting for 75% of all uncomplicated UTIs [5]. Recurrent UTIs are a common problem for young women, causing significant morbidity and care-associated cost [6,7]. The neonatal meningitis-associated *E. coli* (NMEC) is one of the leading causes of early- and late-onset neonatal meningitis and sepsis [8,9].

Resistance to commonly used antibiotics such as fluoroquinolones, tetracycline and cephalosporins is now widespread in both InPEC and ExPEC [1,5,7,10,11]. The extent of multidrug resistance (MDR), including to last-line antibiotics such as carbapenems, tigecyclin and colistin [12–14], is becoming a growing concern, especially in the developing world, where treatment options are limited. For many in the scientific and clinical community, vaccines represent one of the most promising approaches to address the ever-increasing antibiotic resistance in pathogenic *E. coli*. The usual suspects such as toxins, adhesins, and siderophores, all important for colonization and virulence of the pathogen, have been targeted as potential vaccine antigens and explored *in vivo* for their immunological and protective properties [7,15–18]. Despite some positive leads, few have gone through clinical trials, and results have had limited success. Among the many difficulties, the high antigenic diversity and virulence factor redundancy of *E. coli* have undoubtedly hampered the identification of a vaccine protective against various members of a specific pathotype, and support the idea that broad protection against pathogenic *E. coli* will most likely be reached through a vaccine containing multiple antigens. In this regard, reverse vaccinology [19] has offered the opportunity to search and rapidly identify, using bioinformatics, potential vaccine candidates that would be secreted or present on the cell surface of multiple *E. coli* pathogenic strains.

Using this strategy on several ExPEC strains, our group has identified protein SsIE (for Secreted and Surface-associated Lipoprotein of *E. coli*), also known as ECOK1_3385 or YghJ, as a protective vaccine candidate in a murine sepsis model with NMEC [20]. Additional immunization studies showed SsIE to also be protective against other ExPEC strains in different animal models [20,21], as well as an InPEC strain. Furthermore, analysis of human sera of convalescent patients from urosepsis [22] or ETEC infections [23,24] revealed the presence of SsIE-specific antibodies, confirming the immunogenicity of SsIE. Functionally, SsIE was characterized as a mucin-degrading metallopeptidase [25], and shown *in vitro* to degrade several mucins including MUC2, the most common intestinal mucin [21,25]. A series of assays has demonstrated that SsIE mucinase activity helps *E. coli* penetration through the mucus layer, a step that could favor colonization by allowing bacteria to better reach the epithelial layer [25,26]. SsIE has also been associated with biofilm formation in EPEC [27] and, more recently, with significant tissue damage and hemorrhage in mouse ilea [28], further supporting the role of SsIE as an important virulence factor. The SsIE-encoding gene is widely distributed in the *E. coli* phylogeny, with a higher presence in intestinal and extraintestinal pathogenic isolates (between 70% and 83%) compared to commensal isolates (59%) [20]. In a recent study, SsIE was found to be present in 70% of all strains of an *E. coli* data set containing 1700 complete or draft genome sequences spanning commensals and pathotypes from human and animal origins [22].

Overall, SsIE represents a very promising component for a broad-protective vaccine, as it is immunogenic, protective, conserved among different pathotypes, and could play a key role in

pathogenic *E. coli* virulence and disease. Yet, very little is known about the mechanism behind SsIE protective efficacy. In this study, we selected SsIE as model antigen to further characterize the immune response against *E. coli* in mice, with the aim of determining whether a regimen exists that would give robust mucosal and systemic responses. Because the response generated mucosally and systemically can be heavily influenced by the route of immunization chosen, we wanted to take a comparative approach by looking at mucosal-only (intranasal, or i.n), parenteral-only (intramuscular, or i.m), as well as a mixed immunization regimen. It is now well-established that mixing mucosal and parenteral immunizations can have significant benefits in the immune response generated versus mucosal-only or parenteral-only [29–33]; we therefore hypothesized that using a mixed immunization approach would induce a greater immune response, both at the mucosa and systemically. Here, we indeed show that immunizations with SsIE using as priming an i.n dose, followed by two i.m boosts (referred as i.n / i.m / i.m), provided the most robust cellular and humoral responses in both the small intestine lamina propria (LP) and the systemic environment, compared to either i.n-only or i.m-only immunizations. Additionally, considering the known presence of antigen SsIE in several *E. coli* commensals, we were particularly interested at investigating the effect of an intestinal immune response to SsIE on the resident gut microbiota. The influence of the gut microbiota on human health is now well-acknowledged; its disruption has a critical impact on the development and maintenance of the intestinal immune system, and on the onset of severe diseases [34]. Thus, ensuring that an immunization effect on the gut immune response does not perturb the microbiota is paramount. Analysis of the microbial population from both fecal and cecal contents of mice immunized i.n / i.m / i.m reveals no changes to a significant level of the overall composition at the phylum level, and the composition profiles at both family and genus levels appear undisturbed in the cecum before and after immunizations. Together, these results provide the first in-depth immunological profile associated with antigen SsIE, and set important groundwork for the use of SsIE in future vaccine and clinical studies.

2. Materials and Methods

2.1. Formulation with antigen SsIE

Cloning, expression and purification of the NMEC IHE3034 strain SsIE recombinant protein were performed as previously described [21]. The batch of recombinant SsIE used to perform our experiments was determined to have a purity of 94%, and an endotoxin level below 0.07 EU/ μ g. Before each immunization, antigen SsIE was freshly dialyzed using a Slide-A-Lyser dialysis cassette 10 K MWCO (ThermoFisher Scientific) overnight in PBS 1X in order to remove the glycerol used (40%) to store the antigen at - 20 °C. The antigen was then concentrated using a 15 ml centrifugal filter unit 50 K MWCO (Millipore); the final antigen concentration was determined by using the Pierce BCA Protein Assay Kit (ThermoFisher Scientific) according to the manufacturer's recommendations.

For i.n immunizations, we used cholera toxin (CT, Sigma) as adjuvant; we combined 10 μ g of recombinant SsIE with 3 μ g of CT in formulations for a final volume of 10 μ l per mouse. For i.m immunizations, we used an oil-in-water emulsion adjuvant, named SEA for Self-Emulsifying-Adjuvant, which was manufactured as previously described [35]; we combined 10 μ g of antigen SsIE in a 1:1 ratio with SEA in formulations for a final volume of 20 μ l per mouse. Each formulation was freshly prepared the day of immunization, using PBS 10X (Ambion) diluted with Water For Injection (WFI). Each formulation batch was inspected for pH

(range of 7.4 ± 0.5) and osmolality (range of 300 ± 60 mOsm/kg). Antigen and adjuvant characterizations were also performed by running each formulation by SDS-PAGE to verify the presence and integrity of each component upon formulation. In particular, for intramuscular formulations, the soluble part of the formulation (the subnanant) was isolated by ultracentrifugation at 60,000 rpm and used in the SDS-PAGE to confirm the antigen stability in the formulation.

2.2. Mice and immunizations

Protocols were approved by the Italian Ministry of Health (authorization number 689/2015-PR). All mice were housed under specific pathogen-free (SPF) conditions, in accordance with institutional guidelines, at the GSK Vaccines Animal Resource Center, which is an AAALAC (Association of Assessment and Accreditation of Laboratory Animal Care) accredited facility. Four groups of ten eight-week old BALB/c mice were immunized with SsIE or PBS three times, four weeks apart, at days 1, 29 and 57 (Fig. 1): an i.n.-only group i.n / i.n / i.n, an i.m.-only group i.m / i.m / i.m, a mixed immunization group i.n / i.m / i.m, and a naive group receiving PBS pH = 7.4 i.n / i.m / i.m. Immunizations were given as 5 μ l per nostril on anesthetized animals when done intranasally, and in the quadriceps when done intramuscularly.

2.3. In vitro restimulation of antigen-specific CD4⁺ T cells and intracellular cytokines staining

To measure CD4⁺ T cell responses, spleens were harvested and single-cell suspensions were prepared. Splenocytes were plated at 2×10^6 cells/well in 96-well U-bottom plates in RPMI-1640 medium (Gibco-Life Technologies) supplemented with 25 mM HEPES (Gibco-Life Technologies), 10% heat-inactivated FBS (low endotoxin; HyClone, Logan, UT), 1X Pen/Strep/Glut (100X; Gibco-Life Technologies) and 50 μ M B-mercaptoethanol (Sigma), and stimulated with 10 μ g/ml SsIE for 2 h before the addition of 5 μ g/ml of Brefeldin A (Sigma) for 4 h at 37 °C + 5% CO₂. Cells were then washed and stained with Live/Dead Fixable Near-IR viability marker (Molecular Probes-Life Technologies). Cells were then fixed and permeabilized with Cytofix/Cytoperm (BD Biosciences), washed with Perm/Wash buffer (BD Biosciences) and stained with the following antibodies: BV605-labelled anti-CD3 (BD Biosciences), PE-CF594-labelled anti-CD8, BV510-labelled anti-CD4 (Biolegend), V450-labelled CD44, A-488-labelled anti-TNF α (BD Biosciences), BV785-labelled anti-IFN γ (Biolegend), PE-Cy5-labelled anti-IL-2

(Biolegend), PerCP eFluor710-labelled IL-4 and IL-14 (eBioscience), PE-Cy7-labelled anti-IL-17 (eBioscience), all resuspended in Perm/Wash 1X solution. Cells were acquired on an LSR II flow cytometer (BD Biosciences) and analyzed with FLOWJO software (TreeStar). Double-positive cells for CD44 and CD4 were gated on IL-2, IFN- γ , IL-17, IL-4 and IL-13.

2.4. ELISA assays

For all ELISA assays, we used 96 well Nunc-Immuno MicroWell MaxiSorp flat bottom plates (ThermoFisher Scientific). Plates were coated with 100 μ l of antigen SsIE at 1 μ g/ml in PBS pH 7.4 overnight at 4 °C. Plates were blocked for 1 h at 37 °C + 5% CO₂ with PBS + 0.05% Tween 20 + 2% BSA heat shock fraction (Sigma-Aldrich). Plates were then incubated with diluted serum, intestinal washes, or fecal pellet supernatants (in series of 2X dilutions) in PBS + 2% BSA for 2 h at 37 °C + 5% CO₂. For each assay, 100 μ l of goat anti-mouse secondary antibody coupled to alkaline phosphatase was added at the appropriate dilution in PBS + 2% BSA and incubated for 2 h at 37 °C + 5% CO₂: anti-IgG (H+L) at 1:2000, anti-IgA at a dilution of 1:1000, anti-IgG1, anti-IgG2a and anti-IgG2b at a dilution of 1:2000 (all antibodies from SouthernBiotech). Between each of these steps, plates were washed three times with PBS-0.05% Tween 20. Plates were then incubated with 100 μ l of p-nitrophenyl-phosphate liquid substrate (Sigma-Aldrich) for 30 min at room temperature then immediately read on a SpectraMax microplate reader (Molecular Devices) at 405 nm. The linear part of the curve was used for calculating titers at a cutoff value of 0.1 (for sera) or 0.5 (for intestinal washes and fecal pellets).

2.5. Lamina propria cells (LPC) cytokine quantification

Purification of LPC from mouse small intestine (SI) was adapted from a previously described protocol [36]. At the end of the immunization schedule, whole SI tissue was cut and incubated twice in PBS 1X (Gibco-Life Technologies) supplemented with 10% heat-inactivated FBS (low endotoxin; HyClone, Logan, UT), 5 mM EDTA (Sigma) and 1 M HEPES (Gibco-Life Technologies) for 20 min at 37 °C, shaking. The precipitate, containing the LPC, was further cut before being digested in RPMI supplemented with 10% FBS, 100 U/ml collagenase type VIII (Sigma) for 20 min. Cells were then washed, passed through a 70 μ m nylon cell strainer and resuspended in 100% Percoll (GE Healthcare Life Sciences), which was overlaid with 40% percoll, and centrifuged for 20 min at




Fig. 1. Study design for the animal experiments. For each experiment (two independent experiments), three immunization groups with SsIE and one control (PBS) group were used (n = 10 mice per group). i.n / i.m / i.m: intranasal immunization at day 1, intramuscular immunizations at days 29 and 57. i.n / i.n / i.n: intranasal immunizations at days 1, 29 and 57. i.m / i.m / i.m: intramuscular immunizations at days 1, 29, 57. For each group, samples were taken for analysis at day 0 (preimmune stage), or day 71. For microbiota analysis, only PBS i.n / i.m / i.m and SsIE i.n / i.m / i.m were used, with n = 6.

2100 rpm with no break. LPC were recovered from the interface layer. Viability was verified to be > 80% using the Nucleocounter NC-250™ (Chemometec) and staining cells with a solution of acridine orange and DAPI (Solution 18; Chemometec). LPC were plated at 2×10^6 cells/well in 96-well U-bottom plates in RPMI-1640 medium (Gibco-Life Technologies) supplemented with 25 mM HEPES (Gibco-Life Technologies), 10% heat-inactivated FBS (low endotoxin; HyClone), 1X Pen/Strep/Glut (100X; Gibco-Life Technologies) and 50 μ M B-mercaptoethanol (Sigma), and stimulated with 10 μ g/ml SsIE for 24 h at 37 °C + 5% CO₂. Plates were then centrifuged for 10 min at 2000 rpm and supernatants were collected and placed at -80 °C until ready to process.

Each supernatant was quantified for IL-1 β , IL-2, IL-4, IL-5, IL-13, TNF α , IFN- γ , IL-17A, IL-17F, IL-21 and IL-22 using a custom made Meso Scale Discovery U-PLEX mouse Biomarker Group 1 Assays (Meso Scale Discovery) according to the manufacturer's instructions. Plates were read using the QuickPlex SQ 120 imager (Meso Scale Discovery).

2.6. Genomic DNA extraction and microbiota composition analysis

Fecal pellets were collected at day 0 and day 71, along with cecal contents at day 71 (Fig. 1) for six mice of the PBS-immunized group and six mice of the i.n / i.m / i.m group (three mice per cage for each group). All samples were immediately stored at -80 °C until ready to process. Genomic DNA from all samples was isolated based on a previously published protocol [37]. Samples were sent for Illumina sequencing and analysis of bacterial population at Life Sequencing (Valencia, Spain), using the capture of the hyper-variable regions V3-V4 of the ribosomal gene 16 s according to previous literature [38]. On average, 75,000 sequences (62,794–97,213 sequences) were recovered from our samples.

2.7. Statistics

All statistics were made using GraphPad Prism (San Diego, California). Statistical significance (for all assays but the microbiota analysis) was calculated using analysis of variance (ANOVA) with Dunnett's post test. A Mann-Whitney two-tailed test was used to compare the microbiota relative abundance between PBS-immunized and SsIE-immunized mice. Significance is calculated as * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$; ns, not significant ($P \geq 0.05$).

3. Results

3.1. Effect of various SsIE immunization regimens on the gut immune response

We first investigated the effect of i.n-only, i.m-only, and i.n / i.m / i.m immunizations on the mucosal immune response. Lamina propria cells (LPC) were isolated from small intestines at day 71, and the levels of secreted cytokines released in the supernatant after 24 h of *in vitro* re-stimulation with antigen SsIE were measured using MSD technology (Fig. 2). When comparing the i.n / i.m / i.m and i.n / i.n / i.n routes, our results showed that LPC produced cytokines associated with Th1 (IFN- γ , TNF- α , IL-2), Th2 (IL-4, IL-5, IL-13) and Th17 (IL-17A, IL-17F, IL-21 and IL-22) responses in both these groups. Interestingly, although the levels of Th1 cytokines produced were nearly identical in both protocols, we observed a statistically significant increase in Th2 cytokines when mice were immunized through the i.n / i.m / i.m routes, notably with a > 5-fold increase of IL-13. The i.n-only immunizations led, on the other hand, to a 2.5-fold increase of IL-17A compared to the i.n / i.m / i.m routes. The levels of recovered cytokine were

similar between i.n-only and mixed immunization groups for IL-17F, as well as for IL-22, for which we roughly obtained a 12-fold increase compared to naive mice. As for i.m / i.m / i.m immunizations, this regimen only gave a very limited cytokine response in the small intestine (SI), at least for the panel of cytokines that we investigated.

These results showed that, within the protocols tested, an i.n prime immunization is important to induce a Th1, Th2 and Th17 responses in the SI. The i.m boosts seem to result in a greater induction of Th2 cytokines, while the i.n boosts increase production of IL-17A after antigen recall. Overall, both i.n / i.n / i.n and i.n / i.m / i.m immunization protocols appear to be efficient at inducing a robust intestinal T cell response to antigen SsIE.

The gut humoral immune response often plays a critical role in protective immunity against enteric pathogens [39], so we looked at the effects of each of the various immunization protocols on the release of antigen-specific secreted immunoglobulin A (SIgA) antibodies. To do so, we quantified by ELISA SsIE-specific SIgA titers recovered in both intestinal washes and fecal pellets at day 71 (Fig. 3). Similarly to the cellular response in the small intestine LP, results obtained with i.m / i.m / i.m immunizations were limited, with virtually no detectable levels of SIgAs. On the other hand, i.n / i.n / i.n or i.n / i.m / i.m regimens were able to induce detectable SIgA titers that were of the same magnitude when measured in intestinal washes; however, the median SIgA titer recovered from fecal pellets was 5 times higher with i.n / i.m / i.m than with i.n / i.n / i.n immunizations. Thus, the mixed i.n / i.m / i.m protocol generates just as high, if not more, levels of SsIE-specific SIgAs versus a mucosal-only, i.n / i.n / i.n protocol.

3.2. Effect of various SsIE immunization regimens on the systemic immune response

Since we consider SsIE to be a strong candidate as part of a universal vaccine against both InPEC and ExPEC strains, we wanted to assess not only the intestinal immune response, but also the systemic immune response to antigen SsIE. To look at and compare the cellular immune response to antigen SsIE after our different immunization protocols, splenocytes were isolated at day 71 and re-stimulated *in vitro* with antigen SsIE for 6 h (with the last 4 h with Brefeldin A). We then performed an intracellular staining in order to quantify by flow cytometry the cytokine response of effector memory T cells after antigen recall, which is presented as frequency of the total amount of CD4⁺/CD44⁺ T cells recovered (Fig. 4). For all of the cytokines tested, the i.n / i.m / i.m immunization protocol led to a greater percentage of cytokine-positive cells compared to either i.n / i.n / i.n or i.m / i.m / i.m regimens. Indeed, when compared to the i.n-only immunizations, i.n / i.m / i.m immunizations led to at least 4 times more TNF- α and IL-2- positive CD4⁺/CD44⁺ T cells, as well as nearly 3 times more IL-17- positive CD4⁺/CD44⁺ T cells. Noteworthy, we recovered IFN- γ and IL-4/IL-13- positive cells only in splenocytes from mice immunized i.n / i.m / i.m. On the other hand, very few cells recovered from mice immunized with the i.m-only protocol were positive for Th1 cytokines (IFN- γ , TNF- α and IL-2), and none were apparently positive for the Th2 or Th17 cytokines tested.

To look into the serum antibody response, we performed ELISA assays using sera from mice at day 71, which we compared to the pre-immune sera. The total IgG titers (Fig. 5A) showed that mice immunized via i.n / i.m / i.m routes produced higher amounts of IgGs in the sera compared to either i.n-only or i.m-only routes, for which mice produced similar levels of IgGs, approximately 3 times lower than the mixed immunization protocol. We also sought to look into various IgG subtypes to determine the IgG subclass dominance for each immunization protocol (Fig. 5B). All three immunization regimens led to a predominant production of IgG1




Fig. 2. Cytokine quantification of murine lamina propria cells (LPC) after immunizations. Balb/C mice were immunized intranasally (i.n) or intramuscularly (i.m) with SsIE + adjuvant (CT for i.n, SEA for i.m) or PBS (Naive), and LPC were harvested and purified at day 71. Purified LPC were seeded at 10^6 cells/well and cultured with recall antigen SsIE ($10 \mu\text{g/ml}$ final concentration) for 24 h at 37°C . Supernatants were collected and analyzed for cytokine quantification using the MesoScale Discovery U-PLEX mouse cytokine assay kits. Data are from two independent experiments with ten mice per group, and shown as mean \pm standard deviation. IFN- γ , interferon- γ ; TNF- α , tumor necrosis factor- α ; IL, interleukin.

antibodies, while IgG2a levels were weaker, and IgG2b even lower. For all IgG subclasses tested, mice immunized with SsIE via the i.n / i.m / i.m routes showed higher titers versus i.n-only or i.m-only routes. The ratio IgG2/IgG1 calculated for each of these regimens was lower than 0.5 in all cases, confirming a strong Th2 response for all three regimens (Supplemental Fig. 1). However, we did note that both i.n / i.m / i.m and i.n / i.n / i.n regimens had a statistically significant higher ratio value compared to the i.m / i.m / i.m regimen, indicating a bias, although small, towards a Th1 response with both regimens using i.n immunizations.

Overall, mice immunized with SsIE via the i.n / i.m / i.m routes showed a stronger systemic immune response than those immunized via i.n-only or i.m-only routes, both at the cellular level with higher Th1, Th2 and Th17 cytokines, and at the humoral level with greater amounts of IgG antibodies, in any of the IgG subclasses tested.

3.3. Effect of a mixed i.n / i.m / i.m immunization regimen with antigen SsIE on the gut microbiota of conventional mice.

With the gut being a prime example, it is now well established that mucosal immunity and microbiota constantly and dramatically shape the outcome of one another [40–42]. We focused on the i.n / i.m / i.m regimen, which gave us the strongest overall immune response locally and systemically, to investigate whether immunizations with antigen SsIE would lead to an alteration of the mouse gut microbiota. The question was twofold: to determine whether these immunizations would provoke any sort of dysbiosis in the gut microbiota, and to specifically find out whether immunizations with antigen SsIE, which is present in pathogenic as well as commensal *E. coli* [20], would affect the commensal population to significant, perhaps detrimental levels.




Fig. 3. Quantification of secreted IgA (SIgA) titers after immunizations. Intestinal washes and fecal pellets were harvested at day 71 from Balb/C mice immunized intranasally (i.n) or intramuscularly (i.m) with SsIE + adjuvant (CT for i.n, SEA for i.m) or PBS (Naive). Specific SIgA antibody titers were determined by enzyme-linked immunosorbent assay (ELISA). The bar represents the median of antibody titers for each immunization group. Data are from one (fecal pellets) or two (intestinal washes) independent experiment(s), where each dot represents one mouse.




Fig. 4. Cytokine quantification of murine splenocytes after immunizations. Balb/C mice were immunized i.n / i.m / i.m, i.m / i.m / i.m or i.n / i.n / i.n with SsIE + adjuvant (CT for i.n, SEA for i.m) or PBS (Naive), and splenocytes were harvested and purified at day 71. Splenocytes were seeded at 10^6 cells/well, cultured with recall antigen SsIE ($10 \mu\text{g/ml}$ final concentration) and were incubated for 6 h at 37°C , including 4 h with Brefeldin A. Cells were stained with Live/Dead, fixed and permeabilized, then stained with fluorescent antibodies for flow cytometry acquisition. Data are from two independent experiments with ten mice per group, and shown as mean \pm standard deviation. IFN- γ , interferon- γ ; TNF- α , tumor necrosis factor- α ; IL, interleukin.




Fig. 5. Quantification of IgGs after immunizations. Sera from Balb/C mice immunized i.n / i.m / i.m, i.m / i.m / i.m or i.n / i.n / i.n with SsIE + adjuvant (CT for i.n, SEA for i.m) or PBS (Naive) were taken at day 71. Specific (A) total IgG antibody titers, or (B) IgG1, IgG2a and IgG2b titers were determined by enzyme-linked immunosorbent assay (ELISA). Data are from two independent experiments, where each dot represents one mouse.

We collected fecal pellets from mice immunized with antigen SsIE versus PBS using the i.n / i.m / i.m regimen at days 0 and 71, analyzed their genomic DNA content and compared the resulting data. After immunizations with PBS or SsIE, we recovered the same phyla, and in similar proportions, than prior to immunizations (Fig. 6A): the Firmicutes and Bacteroidetes represented the vast majority of classified sequences, while the Actinobacteria and Proteobacteria were present in much lower amounts. We did notice a small increase of the Proteobacteria phylum in SsIE-immunized mice at day 71 compared to PBS-immunized mice.

The Shannon diversity index, which accounts for abundance and evenness, remained high at roughly 1.5 at the family level (Fig. 6B), and 2.1 at the genus level (data not shown) in both PBS and SsIE-immunized mice compared to pre-immunization. We looked more closely at the microbiota composition at the family level in the fecal pellets pre- and post-immunizations (Fig. 6C, upper panels). We recovered the same families before and after immunizations, but observed some fluctuations of the relative abundance over time. Notably, the relative abundance of the Firmicutes Lactobacillaceae and Lachnospiraceae changed substantially from pre- to post-immunizations. All pre-immunized mice showed a relative abundance of Lactobacillaceae of roughly 35% and a lower abundance of Lachnospiraceae at roughly 17%. In PBS-immunized mice, we recovered 24% of Lactobacillaceae and 30% of Lachnospiraceae in fecal pellets; in SsIE-immunized mice, we obtained 10% of Lactobacillaceae and 41% of Lachnospiraceae. Interestingly, when we looked at the microbiota composition from cecal contents post-immunizations (Fig. 6C, lower panels), we did not observe such fluctuations between control and immunized mice at the family level; instead, we obtained a similar distribution for both PBS-treated and SsIE-immunized mice which was comparable to the one recovered from fecal pellets of SsIE-immunized mice from the fecal pellets at day 71, with about 7% of Lactobacillaceae and 44% of Lachnospiraceae. Additionally, the small raise in the relative abundance of Proteobacteria appeared to be the result of an increase in the family Desulfovibrionaceae (Fig. 6C), and more specifically the genus *Desulfovibrio* (data not shown), which was noticeable in both fecal and cecal contents post-immunizations. The relative abundance of *Desulfovibrio* in the cecum, where the difference was the highest, increased from 0.06 ± 0.01 in naive mice to 1.97 ± 0.8 in immunized mice; however, statistical analysis with a Mann-Whitney two-tailed test revealed no significance in this difference. To the extent of our analysis, we recovered neither the genus *Escherichia* nor the Enterobacteriaceae family within the Proteobacteria phylum from our classified sequences prior or post-immunizations, whether in the fecal pellets or the cecum.

Thus, we could not assess whether immunizations with antigen SsIE would affect the commensal *E. coli* in the gut.

Overall, mice immunized with antigen SsIE using the i.n / i.m / i.m regimen maintained the same richness of the microbiota. SsIE-immunized and PBS-immunized mice showed some disparities in the fecal relative abundance of Lachnospiraceae and Lactobacillaceae, but maintained a strikingly similar distribution in the cecal relative abundance of families.

4. Discussion

In this study, we described the immune response to the ExPEC antigen SsIE and the influence of immunizations with SsIE on the gut microbiota. SsIE is a mucin-degrading metalloprotease widely distributed among the many *E. coli* pathotypes, with a highly conserved zinc-metalloprotease core motif [20,21,43]. Functional studies have demonstrated that SsIE is capable of degrading major intestinal mucins such as MUC2 and MUC3 [25]. When *E. coli* is in contact with adherent enterocytes, secretion of SsIE is increased, which is thought to facilitate colonization by degrading mucus and allowing bacteria to reach the surface of enterocytes [26]. SsIE immunizations confer protection, although to various extents, in murine models of ExPEC and InPEC infections, including sepsis, UTI, and intestinal colonization with enterotoxigenic *E. coli* (ETEC) [20,21]. Sera from patients recovering from UTIs or an ETEC infection contain anti-SsIE antibodies [22–24]. Thus, SsIE is conserved in sequence, widely distributed, secreted during infection, and immunogenic, all of which are important characteristics with respect to a potential vaccine candidate.

We sought to better explore this opportunity and investigate the immune response generated against SsIE following various methods of immunization. Our goal was to define the immunization regimen that would deliver the highest mucosal and systemic immune responses, hence bare the potential to be cross-effective against multiple *E. coli* pathotypes. Based on previous studies demonstrating the benefits of combining mucosal with parenteral immunizations [29–33], we set up immunization regimens with either i.n immunizations only, i.m immunizations only, or an i.n prime followed by two i.m boosts. We conclusively showed that mice immunized i.n / i.m / i.m with SsIE mounted a greater overall immune response than those immunized i.n / i.n / i.n or i.m / i.m / i.m.

In the SI, both mixed immunizations and i.n-only immunizations led to a significant cytokine response after *in vitro* antigen restimulation compared to i.m-only immunizations. It is very likely that these responses are antigen-specific CD4⁺ T cell responses,




Fig. 6. Microbiota composition before and after immunizations with SsIE. (A) Normalized phyla relative abundance obtained from fecal pellets of PBS-immunized or SsIE-immunized mice (i.n / i.m / i.m) at days 0 (pre-immunization) and 71 (post-immunization); $n = 6$ for each group. (B) Shannon diversity index obtained at the family level for each group. (C) Microbiota composition (normalized to 100%) at the family level obtained from fecal pellets (upper panels) pre- and post-immunizations or from cecal contents (lower panels) obtained post-immunizations. "Others" represents sequences in clusters where no association has been found.

though we cannot rule out, due to our experimental set up, a non-specific response of other LP lymphoid cells. Notably, for both regimens, we observed a strong induction of the IL-17A, IL-17F and IL-22 cytokines. IL-17A can be secreted by several cells of the LP, including Th17 cells and group 3 innate lymphoid cells (ILC3) [44]. IL-17A and IL-17F, which are thought to share similar biological activities, are important in the initial control of pathogen proliferation through the release of antimicrobial peptides and induction of neutrophil recruitment [45,46]. Deficiency in either one of these cytokines leads to full susceptibility of mice to *C. rodentium* [47], suggesting that these two cytokines are not abso-

lutely redundant and may have some unique biological activities in early gut pathogen control. IL-22, also in part secreted by Th17 cells and ILC3, can act synergistically or additively with IL-17A and IL-17F by increasing antimicrobial peptide secretion and intestinal protection. Previous studies showed that Th17 cells developed in mice after infection with EHEC O157:H7 [48], or immunization with ETEC F4⁺ fimbriae [49]. Th17 cells are also known to be important for the induction of an antigen-specific IgA response by B cells in the germinal center of Peyer's patches in the small intestine [50]. Thus, the presence of these cytokines in the LP after recall with SsIE suggests that IL-17 and IL-22-

secreting cells are specifically induced *in vivo* after SsIE immunizations, mimicking what has been previously observed in other infection and vaccination models.

While we observed a bias towards a higher IL-17A secretion with i.n / i.n / i.n, the i.n / i.m / i.m regimen led to a significantly greater release of Th2-like cytokines. These differences may be attributed to an adjuvant effect. CT, the adjuvant used in i.n immunizations, has been recently shown to induce a balanced Th1/Th2/Th17 response, whether injected mucosally or parenterally [51]; the i.n-only regimen could thus potentially lead to more efficient priming by CT of Th17 cells at each immunization. Likewise, the enhanced Th2-like cytokine levels seen with i.n / i.m / i.m may possibly be attributed to the use of SEA, which has been suggested to behave like most delivery system type of adjuvants by priming Th2 CD4⁺ T cells and enhancing the antibody response.

Besides these important mechanistic questions, our results made evident that the mucosal route of immunization, more than the adjuvant itself, was an essential element in mounting the immune response to SsIE in the SI. Indeed, i.m-only immunizations, regardless of the use of SEA, performed very poorly in the mucosa, with little to no cytokine response recovered in the SI. Similarly, both mixed immunizations and i.n-only immunizations promoted the secretion of anti-SsIE IgAs in the gut, while we could not observe any detectable levels of SIgAs after i.m-only immunizations. Interestingly, the SIgA titers recovered from intestinal lavages were fairly similar between i.n-only and mixed immunizations, yet titers in fecal pellets seemed to be significantly higher in mixed immunizations. Secretions of IgA antibodies in the intestinal lumen represent a crucial element in the immune response against gut bacterial pathogens. In experimental ETEC challenges, infected volunteers all produced mucosal IgAs upon challenge, [52], suggesting that IgA antibodies are indeed an effective arm in the control and/or clearance of ETEC infections.

Thus, with antigen SsIE, i.n-priming seemed to be an essential element in the priming of B and T cells in the gut, and sufficient to induce an immune response of the same magnitude regardless of whether boost immunizations were performed i.n or i.m. It would be interesting to investigate whether the timing of the mucosal immunization is also a critical element for an effective mucosal immune response, by comparing i.n / i.m / i.m immunizations to i.m / i.m / i.n immunizations for example; however, previous studies on immunizations against influenza showed that priming with a mucosal immunization was essential to generate a mucosal immune response [32]. Additionally, the choice of i.n versus another mucosal route could be an important factor in the gut immune response obtained: preliminary results from an equivalent study with SsIE using the sublingual route for mucosal immunizations showed no particular benefit in using the mixed immunization regimen, which instead led to a smaller cellular and humoral immune response in the SI compared to sublingual-only immunizations (unpublished data). Notably, the comparison between intranasal and sublingual immunizations with SsIE revealed a much more reproducible and efficient immune response to the former versus the latter. That said, translating intranasal immunizations with SsIE in potential clinical trials would ultimately warrant the use of another type of mucosal adjuvant; indeed, CT and the structurally similar ETEC heat-labile (LT) enterotoxin present safety risks when used intranasally, even in their detoxified mutant forms [53]. Alternatively, testing other mucosal routes of administration, such as the intradermal route, should be considered in future studies. The differences between i.n / i.m / i.m and i.n-only immunizations were more evident when we quantified the systemic immune response to antigen SsIE. The CD4⁺ T cell response obtained from splenocytes showed a consistently higher percentage of Th1/Th2/Th17 cytokine-positive CD4⁺ T cells when mice were immunized i.n / i.m / i.m versus i.n-only.

These results were paralleled by the serum IgG titers recovered post-immunizations, where i.n / i.m / i.m led to titers of all IgG1, IgG2a and IgG2b far higher than i.n-only immunizations. The i.m-only regimen showed very little systemic T cell response and a much lower IgG antibody titer compared to the mixed immunizations, regardless of the antibody subtype assessed. This finding suggests that an i.n prime immunization with SsIE is critical not only for a mucosal immune response, but also for a systemic immune response. Further, the important difference in both B and T cell responses observed between i.n / i.m / i.m and i.n / i.n / i.n indicates that boosting with parenteral immunizations ensured an efficient mounting of the systemic immune response, at a magnitude not attained with i.n-only immunizations.

In the consideration of a broad-spectrum vaccine against both InPEC and ExPEC, the robust systemic immune response obtained with i.n / i.m / i.m is of particular interest. Indeed, studies have showed that a UTI infection with UPEC resulted in the proliferation of antigen-specific splenic T cells and increase of serum IgG titers, and transfer of either T cells or serum led to protection of naive mice from infection [54]. There may therefore be great benefits associated with a mixed immunization by effectively targeting multiple pathotypes of *E. coli*.

Mucosal immunizations, particularly with an antigen present on the surface of commensals [20,55], must raise the question of the impact of immunizations on the gut microbiota. Choosing i.n / i.m / i.m immunizations to address this possibility, we did not observe any significant change in the overall richness of the microbiota between PBS and SsIE-immunized mice all the way down to the genus level, as indicated by the Shannon diversity index. Accordingly, we recovered the same families and genera between the two groups pre- and post-immunizations, which was an important indicator that immunizations with SsIE did not significantly perturb the overall composition of the gut microbiota.

Within Firmicutes, the relative abundance of the families Lachnospiraceae and Lactospiraceae was markedly different in the fecal pellets of pre- versus post-immunized mice. The high abundance of Lactobacillaceae and lower abundance of Lachnospiraceae in pre-immunized mice was rather surprising, as Lactobacillaceae tend to be in high abundance up only until the ileum, while dropping below 10% in the cecum, colon and feces; as for the Lachnospiraceae, they normally constitute the largest part of the Firmicutes, with a relative abundance at 30% at least [56,57]. However, at day 71, we observed a shift in these two families, whose relative abundance became quite similar to previously reported results [56]; this was the case in fecal and cecal contents of SsIE-immunized mice, and in the cecal content of PBS-immunized mice. This shift could have been due to the transfer of mice from the vendor to our facility. The length of our experimental study could also be at play: immunizations were performed and followed between weeks eight and eighteen; considering the significant age-dependent changes, even in an SPF environment, in the gut microbiota of laboratory mice [58,59], this factor could explain at least part of the changes observed between pre- and post-immunized mice. Additionally, we noticed a different profile of these two families between the fecal content of mock-immunized and SsIE-immunized mice. While we cannot rule out that this difference is influenced by immunizations with SsIE, we believe it is unlikely, as this difference was not perceived in the comparison of the cecal content between these two groups.

The Proteobacteria phylum represents a small component of the microbiota composition, and *E. coli* is generally a poor colonizer of the mouse GI tract [60]. To the extent and depth of our study, we did not find the Enterobacteriaceae family and thus the *Escherichia* genus in our sequence analysis of pre- and post-immunized mice, whether in the feces or the cecum. Although this result was to be expected, assessing whether immunization with SsIE would affect

resident *E. coli* commensals still remains an important question to be addressed in the context of the human gut microbiota. The use of germ-free rats transplanted with a human fecal microbiota [61,62] could be, in this regard, an interesting model to assess this issue. Nevertheless, our results show that a mucosal immunization with SsIE does not perturb the gut microbiota, which we believe is of importance.

In summary, we have described an efficient, mucosal-parenteral immunization schedule with antigen SsIE to induce a robust intestinal and systemic immune response against SsIE, while not significantly disturbing the resident gut microbiota. SsIE thus appears as a potential key component of a broad spectrum vaccine against pathogenic *E. coli*. Although widespread and protective against different *E. coli* pathotypes, SsIE does not cover all known strains [20]. Using the same reverse vaccinology approach against InPEC, our group is currently characterizing some promising vaccine candidates that have showed protective efficacy against an intestinal enterohemorrhagic *E. coli* model of infection. Another approach is to use reverse vaccinology to identify antigens present in the *E. coli* core genome from all pathogenic and non-pathogenic strains. A recent study has identified antigen YncE, present in > 99% of all *E. coli* genomes available, which shows protection against a bacteremia model of infection, and is recognized by antibodies present in the sera of convalescent urosepsis patients [22]. We and others have showed that immunizations with conserved *E. coli* antigens do not perturb to significant extent the murine gut microbiota [63]. Although *E. coli* is a prevalent member of our microflora, it only accounts for about 0.1% of its total composition. The idea of a multi-component broad-spectrum vaccine including candidates such as SsIE and YncE thus deserves to be considered in future vaccine research strategies.

Acknowledgments

We would like to thank all members from the GSK Vaccines Animal Resource Center, FACS facility, and formulation facility at the Siena Research Center, for their great technical support in the realization of this study. Additionally, we thank Maria-Gloria Lopez at INRA for her technical assistance. Thank you to Mathilde Girard-Madoux, from the Centre d'Immunologie de Marseille-Luminy, for her help in experimental set ups and data analysis. We thank Dr. Laureen Crouzet as well as Dr. Bertrand Evrard, from Université Clermont-Auvergne, France, for the many helpful discussions and critical input in this manuscript. Finally, we thank Dr. Marco Soriani for his contribution as initial coordinator of the project funding.

Author contributions

IN, UD and CB conceived the study; IN, CB and BCB designed the experiments; IN and JV performed the experiments; IN, CB, AB-D and GJ analyzed the data; IN wrote the manuscript; all authors reviewed and approved the manuscript.

Funding

This study was funded by the Marie Skłodowska-Curie Actions ITN EID DISCo (A multidisciplinary Doctoral Industrial School on novel preventive strategies against *E. coli* infections; <http://www.discoproject.eu/>; n°FP7-PEOPLE-607611) in which GSK Vaccines and INRA are full partners, and Université Clermont-Auvergne and Università degli studi Roma Tre are associated partners.

Conflict of interest

CB, UD, BCB and MP are current permanent employees at GSK. JV is a former GSK employee and was supported by the People Programme (Marie Skłodowska-Curie Actions) of the European Union's Seventh Framework Programme FP7/2007-2013 under the REA Grant agreement 317057 HOMIN-ITN. Ilham Naili is a former GSK employer and a Marie Curie PhD Research Fellow granted by ITN EID DISCo, whose work was performed at both GSK Vaccines and INRA. All other authors declare no conflict of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.vaccine.2018.10.008>.

References

- [1] Croxen MA et al. Recent advances in understanding enteric pathogenic *Escherichia coli*. *Clin Microbiol Rev* 2013;26(4):822–80.
- [2] Kaper JB, Nataro JP, Mobley HL. Pathogenic *Escherichia coli*. *Nat Rev Microbiol* 2004;2(2):123–40.
- [3] Croxen MA, Finlay BB. Molecular mechanisms of *Escherichia coli* pathogenicity. *Nat Rev Microbiol* 2010;8(1):26–38.
- [4] Havelaar AH et al. World health organization global estimates and regional comparisons of the burden of foodborne disease in 2010. *PLoS Med* 2015;12(12):e1001923.
- [5] Flores-Mireles AL et al. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nat Rev Microbiol* 2015;13(5):269–84.
- [6] Mobley HL, Alteri CJ. Development of a vaccine against *Escherichia coli* urinary tract infections. *Pathogens* 2015;5(1).
- [7] Terlizzi ME, Gribaudo G, Maffei ME. Uropathogenic *Escherichia coli* (UPEC) infections: virulence factors, bladder responses, antibiotic, and non-antibiotic antimicrobial strategies. *Front Microbiol* 2017;8:1566.
- [8] Simonsen KA et al. Early-onset neonatal sepsis. *Clin Microbiol Rev* 2014;27(1):21–47.
- [9] Bonacorsi S, Bingen E. Molecular epidemiology of *Escherichia coli* causing neonatal meningitis. *Int J Med Microbiol* 2005;295(6–7):373–81.
- [10] Amezcua-Lopez BA et al. Isolation, genotyping and antimicrobial resistance of Shiga toxin-producing *Escherichia coli*. *J Microbiol Immunol Infect* 2017.
- [11] Torres AG. *Escherichia coli* diseases in Latin America—a 'One Health' multidisciplinary approach. *Pathog Dis* 2017;75(2).
- [12] Mediavilla JR et al. Colistin- and Carbapenem-Resistant *Escherichia coli* Harboring *mcr-1* and *blaNDM-5*, causing a complicated urinary tract infection in a patient from the United States. *MBio* 2016;7(4):00.
- [13] Pitout JD, DeVinney R. *Escherichia coli* ST131: a multidrug-resistant clone primed for global domination. *F1000Res* 2017;6.
- [14] Pournaras S et al. Current perspectives on tetracycline resistance in Enterobacteriaceae: susceptibility testing issues and mechanisms of resistance. *Int J Antimicrob Agents* 2016;48(1):11–8.
- [15] Bourgeois AL, Wierzbicka TF, Walker RL. Status of vaccine research and development for enterotoxigenic *Escherichia coli*. *Vaccine* 2016;34(26):2880–6.
- [16] Garcia-Angulo VA, Kalita A, Torres AG. Advances in the development of enterohemorrhagic *Escherichia coli* vaccines using murine models of infection. *Vaccine* 2013;31(32):3229–35.
- [17] Mike LA et al. Siderophore vaccine conjugates protect against uropathogenic *Escherichia coli* urinary tract infection. *Proc Natl Acad Sci U S A* 2016;113(47):13468–73.
- [18] O'Ryan M et al. Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic *E. coli* (ETEC) enterohemorrhagic *E. coli* (EHEC) and *Campylobacter jejuni*. *Hum Vaccin Immunother* 2015;11(3):601–19.
- [19] Donati C, Rappuoli R. Reverse vaccinology in the 21st century: improvements over the original design. *Ann N Y Acad Sci* 2013;1285:115–32.
- [20] Moriel DG et al. Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic *Escherichia coli*. *Proc Natl Acad Sci U S A* 2010;107(20):9072–7.
- [21] Nesta B et al. SsIE elicits functional antibodies that impair in vitro mucinase activity and in vivo colonization by both intestinal and extraintestinal *Escherichia coli* strains. *PLoS Pathog* 2014;10(5):e1004124.
- [22] Moriel DG et al. A novel protective vaccine antigen from the core *Escherichia coli* genome. *mSphere* 2016;1(6).
- [23] Luo Q et al. Conservation and immunogenicity of novel antigens in diverse isolates of enterotoxigenic *Escherichia coli*. *PLoS Negl Trop Dis* 2015;9(1):e0003446.
- [24] Roy K et al. Enterotoxigenic *Escherichia coli* elicits immune responses to multiple surface proteins. *Infect Immun* 2010;78(7):3027–35.

- [25] Luo Q et al. Enterotoxigenic *Escherichia coli* secretes a highly conserved mucin-degrading metalloprotease to effectively engage intestinal epithelial cells. *Infect Immun* 2014;82(2):509–21.
- [26] Valeri M, Pathogenic E, et al. coli exploits SsIE mucinase activity to translocate through the mucosal barrier and get access to host cells. *PLoS ONE* 2015;10(3):e0117486.
- [27] Baldi DL et al. The type II secretion system and its ubiquitous lipoprotein substrate, SsIE, are required for biofilm formation and virulence of enteropathogenic *Escherichia coli*. *Infect Immun* 2012;80(6):2042–52.
- [28] Tapader R, Bose D, Pal A, Ygh J, the secreted metalloprotease of pathogenic *E. coli* induces hemorrhagic fluid accumulation in mouse ileal loop. *Microb Pathog* 2017;105:96–9.
- [29] Lasaro MO et al. Combined vaccine regimen based on parenteral priming with a DNA vaccine and administration of an oral booster consisting of a recombinant *Salmonella enterica* serovar Typhimurium vaccine strain for immunization against infection with human-derived enterotoxigenic *Escherichia coli* strains. *Infect Immun* 2004;72(11):6480–91.
- [30] Layton GT, Smithyman AM. The effects of oral and combined parenteral/oral immunization against an experimental *Escherichia coli* urinary tract infection in mice. *Clin Exp Immunol* 1983;54(2):305–12.
- [31] Pierce NF, Sack RB, Sircar BK. Immunity to experimental cholera. III. Enhanced duration of protection after sequential parenteral-oral administration of toxoid to dogs. *J Infect Dis* 1977;135(6):888–96.
- [32] Vajdy M et al. A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza. *Clin Immunol* 2007;123(2):166–75.
- [33] Vajdy M et al. Enhanced mucosal and systemic immune responses to *Helicobacter pylori* antigens through mucosal priming followed by systemic boosting immunizations. *Immunology* 2003;110(1):86–94.
- [34] Clemente JC et al. The impact of the gut microbiota on human health: an integrative view. *Cell* 2012;148(6):1258–70.
- [35] Shah RR et al. The development of self-emulsifying oil-in-water emulsion adjuvant and an evaluation of the impact of droplet size on performance. *J Pharm Sci* 2015;104(4):1352–61.
- [36] Girard-Madoux MJ et al. IL-10 control of CD11c⁺ myeloid cells is essential to maintain immune homeostasis in the small and large intestine. *Oncotarget* 2016;7(22):32015–30.
- [37] Godon JJ et al. Molecular microbial diversity of an anaerobic digester as determined by small-subunit rDNA sequence analysis. *Appl Environ Microbiol* 1997;63(7):2802–13.
- [38] Klindworth A et al. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. *Nucleic Acids Res* 2013;41(1):e1.
- [39] Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. *Vaccine* 2007;25(30):5467–84.
- [40] Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. *Cell* 2014;157(1):121–41.
- [41] Brown EM, Sadarangani M, Finlay BB. The role of the immune system in governing host-microbe interactions in the intestine. *Nat Immunol* 2013;14(7):660–7.
- [42] Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. *Nat Rev Immunol* 2009;9(5):313–23.
- [43] Nakjang S et al. A novel extracellular metalloprotease domain shared by animal host-associated mutualistic and pathogenic microbes. *PLoS ONE* 2012;7(1):e30287.
- [44] Das S, Khader S. Yin and yang of interleukin-17 in host immunity to infection. *F1000Res* 2017;6:741.
- [45] Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. *Immunity* 2008;28(4):454–67.
- [46] Valeri M, Raffatellu M. Cytokines IL-17 and IL-22 in the host response to infection. *Pathog Dis* 2016;74(9).
- [47] Ishigame H et al. Differential roles of interleukin-17A and -17F in host defense against mucocutaneous bacterial infection and allergic responses. *Immunity* 2009;30(1):108–19.
- [48] Atarashi K et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. *Cell* 2015;163(2):367–80.
- [49] Luo Y et al. F4+ ETEC infection and oral immunization with F4 fimbriae elicits an IL-17-dominated immune response. *Vet Res* 2015;46:121.
- [50] Hirota K et al. Plasticity of Th17 cells in Peyer's patches is responsible for the induction of T cell-dependent IgA responses. *Nat Immunol* 2013;14(4):372–9.
- [51] Mattsson J et al. Cholera toxin adjuvant promotes a balanced Th1/Th2/Th17 response independently of IL-12 and IL-17 by acting on G α in CD11b(+) DCs. *Mucosal Immunol* 2015;8(4):815–27.
- [52] Levine MM et al. Immunity to enterotoxigenic *Escherichia coli*. *Infect Immun* 1979;23(3):729–36.
- [53] Lewis DJ et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of *Escherichia coli* heat labile toxin. *PLoS ONE* 2009;4(9):e6999.
- [54] Thumbikat P et al. Antigen-specific responses accelerate bacterial clearance in the bladder. *J Immunol* 2006;176(5):3080–6.
- [55] Decanio MS, Landick R, Haft RJ. The non-pathogenic *Escherichia coli* strain W secretes SsIE via the virulence-associated type II secretion system beta. *BMC Microbiol* 2013;13:130.
- [56] Gu S et al. Bacterial community mapping of the mouse gastrointestinal tract. *PLoS ONE* 2013;8(10):e74957.
- [57] Pang W et al. Faecal and caecal microbiota profiles of mice do not cluster in the same way. *Lab Anim* 2012;46(3):231–6.
- [58] Langille MG et al. Microbial shifts in the aging mouse gut. *Microbiome* 2014;2(1):50.
- [59] Lundberg R et al. Microbiota composition of simultaneously colonized mice housed under either a gnotobiotic isolator or individually ventilated cage regime. *Sci Rep* 2017;7:42245.
- [60] Xiao L et al. A catalog of the mouse gut metagenome. *Nat Biotechnol* 2015;33(10):1103–8.
- [61] Crouzet L et al. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. *Neurogastroenterol Motil* 2013;25(4):e272–82.
- [62] Le Bihan G et al. Transcriptome analysis of *Escherichia coli* O157:H7 grown in vitro in the sterile-filtrated cecal content of human gut microbiota associated rats reveals an adaptive expression of metabolic and virulence genes. *Microbes Infect* 2015;17(1):23–33.
- [63] Hays MP et al. Vaccinating with conserved *Escherichia coli* antigens does not alter the mouse intestinal microbiome. *BMC Res Notes* 2016;9(1):401.